Takeda Update Regarding Colcrys® Litigation
WEBNov 5, 2014 · On October 6, Takeda filed a lawsuit against the FDA for violation of the Administrative Procedure Act (APA) for its approval of the Hikma Pharmaceuticals (“Hikma”) and West-Ward Pharmaceuticals (“West-Ward”) colchicine product.
Takeda loses again to Hikma in gout drug patent battle
WEBMay 24, 2016 · In September 2014, it approved Hikma’s version of colchicine to prevent gout flares. The agency’s move prompted Takeda to file a patent infringement suit against Hikma and the agency.
Federal Judge Sides With FDA in Colchicine 505 (b) (2 ... - FDAnews
WEBJan 20, 2015 · Federal Judge Sides With FDA in Colchicine 505 (b) (2) Approval Lawsuit. Hikma Pharmaceuticals will launch its gout treatment, Mitigare, after a federal court rejected Takeda’s arguments to block the product, which would compete with …
Hikma wins dismissal of Takeda patent lawsuit over gout drug
WEBMay 20, 2016 · A federal court has cleared the way for Hikma Pharmaceuticals Plc to continue selling a drug with the same active chemical as Takeda Pharmaceutical Co's gout drug Colcrys, dismissing a patent...
Takeda Pharma., U.S.A. v. Hikma Am., Inc., No. 15-1139 ... - Justia Law
WEBMay 6, 2015 · Takeda has patents directed to treating acute gout flares and others directed to methods for administering colchicine for prophylaxis of gout in patients who are concomitantly taking certain drug inhibitors known as “CYP3A4” and “P-gp” inhibitors.
District Court sets accelerated date to resolve Takeda suit against …
WEBNov 10, 2014 · Takeda filed a law suit against the FDA for violation of the Administrative Procedure Act for its approval of a colchicine product manufactured by Jordanian company Hikma (LSE: HIK) and USA-based West-Ward Pharmaceuticals.
WEBJul 31, 2020 · In 2016, Takeda sued Mylan Pharmaceuticals Inc. for patent infringement based on Mylan’s recently submitted Abbreviated New Drug Application (“ANDA”) for a generic version of Takeda’s Colcrys® product, which is …
Hikma to launch colchicine in USA as Takeda’s injunction fails
WEBJan 13, 2015 · Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) saw its shares rise 4.2% to a record high of £23.80, after a USA appeals court rejected Japanese drug major Takeda Pharmaceutical’s (TY0: 4502) bid …
Takeda's Claims Dismissed against West-Ward & Hikma Over COLCRYS…
WEBMay 20, 2016 · U.S. District Court of Delaware dismissed Takeda’s lawsuit finding that West-Ward and Hikma could not have induced the infringement of Takeda’s drug-drug interaction patents. Takeda makes...
Judge finds Hikma entitled to $31 mln in gout drug dispute
WEBDec 14, 2018 · Hikma Pharmaceuticals PLC did not infringe rival Takeda Pharmaceutical Co's patents by selling a gout drug with the same active ingredient as Takeda's Colcrys and is entitled to $31 million in...